Report cover image

Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Dec 29, 2025
Length 63 Pages
SKU # GBDT20700074

Description

Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Newron Pharmaceuticals SpA (Newron) is a biopharmaceutical company. It focuses on the development of novel therapies for diseases of the central and peripheral nervous system. The company’s marketed the product, Xadago (safinamide), which is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain and Evenamide (NW-3509) for the treatment of schizophrenia. The company's main activities include the research and development of innovative treatments for central nervous system disorders and pain management. It has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. The company has an international presence, with products approved in countries including Switzerland, the US, Australia, Canada, and Japan. Newron is headquartered in Bresso, Milan, Italy.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

63 Pages
Section 1 - About the Company
Newron Pharmaceuticals SpA - Key Facts
Newron Pharmaceuticals SpA - Key Employees
Newron Pharmaceuticals SpA - Key Employee Biographies
Newron Pharmaceuticals SpA - Major Products and Services
Newron Pharmaceuticals SpA - History
Newron Pharmaceuticals SpA - Company Statement
Newron Pharmaceuticals SpA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Newron Pharmaceuticals SpA - Business Description
R&D Overview
Newron Pharmaceuticals SpA - Corporate Strategy
Newron Pharmaceuticals SpA - SWOT Analysis
SWOT Analysis - Overview
Newron Pharmaceuticals SpA - Strengths
Newron Pharmaceuticals SpA - Weaknesses
Newron Pharmaceuticals SpA - Opportunities
Newron Pharmaceuticals SpA - Threats
Newron Pharmaceuticals SpA - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Newron Pharmaceuticals SpA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 21, 2025: Beijing Xinghao Pharmaceutical and More Than 20 Pharmaceutical Companies Are Competing for the First Generic Version of Parkinson’s Disease Drug!
Oct 02, 2025: Newron Presents Updates on Evenamide Clinical Program for Schizophrenia at ECNP Congress 2025
Oct 02, 2025: Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025
Sep 16, 2025: Newron Reports H1 2025 Results And Business Update
Apr 01, 2025: Newron Presents 2024 Financial Results and Provides 2025 Outlook
Mar 24, 2025: Newron Proposes Renowned Biopharma Company Founder and Entrepreneur Dr. Chris Martin for Election as Independent Chairman
Jan 10, 2025: Newron and Myung In Pharm sign agreement for evenamide development
Sep 19, 2024: Newron Reports H1 2024 Results and Announces Business Update
Sep 19, 2024: Newron Presents H1 2024 Results and Provides Business Update
Mar 19, 2024: Newron Presents 2023 Financial Results and Provides 2024 Outlook
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Newron Pharmaceuticals SpA, Key Facts
Newron Pharmaceuticals SpA, Key Employees
Newron Pharmaceuticals SpA, Key Employee Biographies
Newron Pharmaceuticals SpA, Major Products and Services
Newron Pharmaceuticals SpA, History
Newron Pharmaceuticals SpA, Subsidiaries
Newron Pharmaceuticals SpA, Key Competitors
Newron Pharmaceuticals SpA, Ratios based on current share price
Newron Pharmaceuticals SpA, Annual Ratios
Newron Pharmaceuticals SpA, Annual Ratios (Cont...1)
Newron Pharmaceuticals SpA, Annual Ratios (Cont...2)
Newron Pharmaceuticals SpA, Interim Ratios
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Newron Pharmaceuticals SpA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Newron Pharmaceuticals SpA, Performance Chart (2020 - 2024)
Newron Pharmaceuticals SpA, Ratio Charts
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.